Psychedelic Research Booms, CEO Suggests “Natural” Drugs for Treatment

( — In an interview with the Associated Press, the CEO of the Vancouver-based psychedelic start-up Filament Health discussed his company’s unique approach to making psychedelic drugs like mescaline and psilocybin by extracting the substances from natural sources rather than creating them synthetically.

There has been an increase in research on the use of psychedelics as possible alternative treatments for addiction, post-traumatic stress disorder, depression, and other conditions. But rather than create the drugs synthetically in a lab, Filament extracts them organically from plant sources like cacti and mushrooms.

According to CEO Benjamin Lightburn, Filament has been researching its mushroom-extracted psilocybin to treat opioid and stimulant addiction. Additionally, over a dozen companies and researchers have conducted trials on the use of Filament’s psilocybin for treating depression, chronic pain, and other conditions.

According to Lightburn, Filament’s psychedelics are derived from natural sources like fungi and plants in much the same way people have used those sources for thousands of years.

Lightburn said natural sourcing puts Filament at an advantage over other companies manufacturing psychedelics. He told the Associated Press that the company has successfully manufactured the drugs and gotten them into clinical trials.

According to Lightburn, there is significant interest in Filament’s psychedelic drugs from researchers worldwide. He said there is also a great deal of interest from investors who want to fund the company’s “internal drug development.”

Lightburn is confident that if psychedelics prove to be effective and patients would prefer to go the natural route, then his company will be “sticking around for the long haul.”

Copyright 2023,